Loading organizations...
Tenmile is an Australian health technology venture capital firm investing in early-stage companies. It targets science-backed innovations with clinical impact and commercial success, addressing urgent health needs. The firm supports entrepreneurial ventures with reliable capital, prioritizing rigorous research and real-world application for breakthroughs.
Founded in 2022, Tenmile emerged from a vision connecting Australian health innovation with global markets. Dr. Steve Burnell is Managing Director, guiding the firm's investment strategy. Owned by Tattarang, a significant Australian private entity, it provides a robust foundation for venture activities and specialized health tech expertise.
Tenmile partners with early-stage health technology companies, offering capital and collaborative support. The firm aims to improve human health globally by nurturing top-tier portfolio companies. Its long-term vision establishes strong links between Australian innovation and international healthcare, fostering scalable solutions for global challenges.
Tenmile has 3 tracked investments across 3 companies. The latest tracked deal is $180.0M Series A in Antares Therapeutics in May 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2025 | Antares Therapeutics | $180.0M Series A | Atlas Venture, Shelley CHU, Otello Stampacchia, BVF Partners, Cormorant Asset Management | Frazier Healthcare Partners, Polaris Partners, Vida Ventures, Invus, Vinyanshu Ventures, Willett Advisors, Abingworth |
| Jun 3, 2024 | Psylo | $8.0M Seed | Tenmile | — |
| Jan 23, 2024 | Aravax | $42.0M Series B | — | Agati Capital, Brandon Capital, Grant Dooley, Novartis, Uniseed |
